Melanoma

FDA Grants Accelerated Approval for RP1 (Tudriqev) With Nivolumab in Advanced Melanoma

The agency based its decision on response‑rate results from a single‑arm IGNYTE trial with continued approval contingent on an ongoing randomized confirmatory study.